Therapy of Canine Hyperlipidemia with Bezafibrate

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMARCO, V. De
dc.contributor.authorNORONHA, K. S. M.
dc.contributor.authorCASADO, T. C.
dc.contributor.authorNAKANDAKARE, E. R.
dc.contributor.authorFLORIO, J. C.
dc.contributor.authorSANTOS, E. Z.
dc.contributor.authorGILOR, C.
dc.date.accessioned2017-08-17T19:14:51Z
dc.date.available2017-08-17T19:14:51Z
dc.date.issued2017
dc.description.abstractBackground: Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective: To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. Animals: Forty-six dogs, 26 females and 20 males, mean (+/-SD) age of 9 (+/-3) years, with TG = 150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). Methods: Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. Results: Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (< 150 mg/dL) in 42 dogs (91.3%) and CHO concentration normalized (< 270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment. Conclusions and Clinical Importance: Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.
dc.description.indexMEDLINE
dc.identifier.citationJOURNAL OF VETERINARY INTERNAL MEDICINE, v.31, n.3, p.717-722, 2017
dc.identifier.doi10.1111/jvim.14701
dc.identifier.issn1939-1676
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21227
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofJournal of Veterinary Internal Medicine
dc.rightsopenAccess
dc.rights.holderCopyright WILEY
dc.subjectCholesterol
dc.subjectHyperadrenocorticism
dc.subjectPeroxisome proliferator-activated receptor
dc.subjectSchnauzer
dc.subjectTriglyceride
dc.subject.otherhealthy miniature-schnauzers
dc.subject.othershetland sheepdogs
dc.subject.otherdogs
dc.subject.otherhypertriglyceridemia
dc.subject.otherassociation
dc.subject.otherhyperlipoproteinemia
dc.subject.otherhyperadrenocorticism
dc.subject.othermetabolism
dc.subject.otherobesity
dc.subject.wosVeterinary Sciences
dc.titleTherapy of Canine Hyperlipidemia with Bezafibrate
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalMARCO, V. De:Univ Santo Amaro, Sao Paulo, Brazil; Univ Guarulhos, Sao Paulo, Brazil; Univ Guarulhos, Vet Hosp, Sao Paulo, Brazil
hcfmusp.author.externalNORONHA, K. S. M.:Univ Guarulhos, Sao Paulo, Brazil; Univ Guarulhos, Vet Hosp, Sao Paulo, Brazil
hcfmusp.author.externalCASADO, T. C.:Univ Guarulhos, Sao Paulo, Brazil; Univ Guarulhos, Vet Hosp, Sao Paulo, Brazil
hcfmusp.author.externalFLORIO, J. C.:Univ Sao Paulo, Vet Med Sch, Sao Paulo, Brazil; Univ Guarulhos, Vet Hosp, Sao Paulo, Brazil
hcfmusp.author.externalSANTOS, E. Z.:Univ Santo Amaro, Sao Paulo, Brazil; Univ Guarulhos, Vet Hosp, Sao Paulo, Brazil
hcfmusp.author.externalGILOR, C.:Univ Calif Davis, 1 Shields Ave, Davis, CA 95616 USA; Univ Guarulhos, Vet Hosp, Sao Paulo, Brazil
hcfmusp.citation.scopus25
hcfmusp.contributor.author-fmusphcEDNA REGINA NAKANDAKARE
hcfmusp.description.beginpage717
hcfmusp.description.endpage722
hcfmusp.description.issue3
hcfmusp.description.volume31
hcfmusp.origemWOS
hcfmusp.origem.pubmed28382723
hcfmusp.origem.scopus2-s2.0-85017454007
hcfmusp.origem.wosWOS:000405196800013
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAbourbih S, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.03.030
hcfmusp.relation.referenceAguirre AL, 2007, JAVMA-J AM VET MED A, V231, P79, DOI 10.2460/javma.231.1.79
hcfmusp.relation.referenceBAUER JE, 1995, J AM VET MED ASSOC, V206, P1684
hcfmusp.relation.referenceBeggs PW, 1999, BRIT J CLIN PHARMACO, V47, P99, DOI 10.1046/j.1365-2125.1999.00846.x
hcfmusp.relation.referenceBehrend EN, 2015, CANINE FELINE ENDOCR, P377
hcfmusp.relation.referenceBerglund L, 2012, J CLIN ENDOCR METAB, V97, P2969, DOI 10.1210/jc.2011-3213
hcfmusp.relation.referenceCRISPIN SM, 1993, J SMALL ANIM PRACT, V34, P500, DOI 10.1111/j.1748-5827.1993.tb03522.x
hcfmusp.relation.referenceElliot DA, 2005, TXB VET INTERNAL MED, P592
hcfmusp.relation.referenceFeldman EC, 2004, CANINE FELINE ENDOCR, P86
hcfmusp.relation.referenceFord RB, 2010, SMALL ANIMAL CLIN NU, P545
hcfmusp.relation.referenceFurrow E, 2016, VET J, V212, P83, DOI 10.1016/j.tvjl.2016.04.009
hcfmusp.relation.referenceHess RS, 2003, J VET INTERN MED, V17, P489, DOI 10.1892/0891-6640(2003)017<0489:ABDMHO>2.3.CO;2
hcfmusp.relation.referenceJerico MM, 2009, J VET DIAGN INVEST, V21, P203
hcfmusp.relation.referenceJeusette IC, 2005, AM J VET RES, V66, P81, DOI 10.2460/ajvr.2005.66.81
hcfmusp.relation.referenceKutsunai M, 2014, VET J, V199, P76, DOI 10.1016/j.tvjl.2013.10.019
hcfmusp.relation.referenceMooney CT, 2012, BSAVA MANUAL CANINE, P63
hcfmusp.relation.referenceROGERS WA, 1975, J AM VET MED ASSOC, V166, P1087
hcfmusp.relation.referenceSando KR, 2015, CLIN THER, V37, P2153, DOI 10.1016/j.clinthera.2015.09.001
hcfmusp.relation.referenceSato K, 2000, J VET MED SCI, V62, P1297, DOI 10.1292/jvms.62.1297
hcfmusp.relation.referenceSchickel R., 2005, THESIS
hcfmusp.relation.referenceSerisier S, 2006, J NUTR, V136, p2037S
hcfmusp.relation.referenceStaels B, 1998, CIRCULATION, V98, P2088
hcfmusp.relation.referenceVitale CL, 2007, J VET INTERN MED, V21, P1316, DOI 10.1892/07-013.1
hcfmusp.relation.referenceWADA M, 1977, LIFE SCI, V20, P999, DOI 10.1016/0024-3205(77)90287-9
hcfmusp.relation.referenceXenoulis PG, 2015, J SMALL ANIM PRACT, V56, P595, DOI 10.1111/jsap.12396
hcfmusp.relation.referenceXenoulis PG, 2011, J VET INTERN MED, V25, P20, DOI 10.1111/j.1939-1676.2010.0644.x
hcfmusp.relation.referenceXenoulis PG, 2008, JAVMA-J AM VET MED A, V232, P63, DOI 10.2460/javma.232.1.63
hcfmusp.relation.referenceXenoulis PG, 2007, J VET INTERN MED, V21, P1224, DOI 10.1892/07-051.1
hcfmusp.relation.referenceXenoulis PG, 2011, JAVMA-J AM VET MED A, V238, P1011, DOI 10.2460/javma.238.8.1011
hcfmusp.relation.referenceXenoulis PG, 2010, VET J, V183, P12, DOI 10.1016/j.tvjl.2008.10.011
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication597642a3-8720-4abe-88ec-e0e57c28c859
relation.isAuthorOfPublication.latestForDiscovery597642a3-8720-4abe-88ec-e0e57c28c859
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MARCO_Therapy_of_Canine_Hyperlipidemia_with_Bezafibrate_2017.PDF
Tamanho:
405.58 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/10